PMC:7195088 / 23935-24145 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T118","span":{"begin":141,"end":149},"obj":"Disease"}],"attributes":[{"id":"A118","pred":"mondo_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint:"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T118","span":{"begin":156,"end":161},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint:"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T306","span":{"begin":58,"end":76},"obj":"Chemical"},{"id":"T307","span":{"begin":82,"end":91},"obj":"Chemical"},{"id":"T308","span":{"begin":92,"end":102},"obj":"Chemical"},{"id":"T309","span":{"begin":156,"end":161},"obj":"Chemical"}],"attributes":[{"id":"A306","pred":"chebi_id","subj":"T306","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A307","pred":"chebi_id","subj":"T307","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A308","pred":"chebi_id","subj":"T308","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A309","pred":"chebi_id","subj":"T309","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint:"}

{"project":"LitCovid-sentences","denotations":[{"id":"T177","span":{"begin":42,"end":150},"obj":"Sentence"},{"id":"T178","span":{"begin":151,"end":192},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"-2 eradication time (follow-up 24 weeks).\n• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. Open-label RCT (NCT04304053, recruiting). Primary endpoint:"}